Showing results (1-10 of 59) with videos related to
Sort By:
Pageof 6
Journal of Clinical Epidemiology|April 11, 2007
Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methodsRichard D Riley, Mark C Simmonds, Maxime P LookStatistics in Medicine|May 3, 2014
Multilevel mixed effects parametric survival models using adaptive Gauss-Hermite quadrature with application to recurrent events and individual participant data meta-analysisMichael J Crowther, Maxime P Look, Richard D RileyBreast Cancer Research : BCR|October 15, 2009
Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis studySzu-Min Hsieh, Maxime P Look, Anieta M Sieuwerts, et al.BMC Cancer|September 12, 2009
Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective studyAnne-Sofie Schrohl, Maxime P Look, Marion E Meijer-van Gelder, et al.Cancer Research|January 25, 2003
The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancerJohn A Foekens, Christian Ries, Maxime P Look, et al.Endocrine-Related Cancer|March 4, 2008
Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancerDanielle Meijer, Anieta M Sieuwerts, Maxime P Look, et al.Breast Cancer Research : BCR|September 13, 2012
High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genesMuhammad Riaz, Anieta M Sieuwerts, Maxime P Look, et al.Head & Neck|December 14, 2006
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinomaLuciënne Speleman, Jeroen D F Kerrebijn, Maxime P Look, et al.Oncotarget|April 16, 2016
Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosisMarjolein J A Weerts, Anieta M Sieuwerts, Marcel Smid, et al.Clinical Breast Cancer|December 9, 2004
Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancerNadia Harbeck, Roanld E Kates, Manfred Schmitt, et al.Pageof 6